| |
|
| |
 |
| |
Letter from Chairman and Founder
Our motto is to ‘accelerate Pharma time-to-market cost effectively with no compromise in quality’ in clinical development for sponsors. 2009 was a successful year when we grew in excess of 30% and ended with a record backlog.
- We demonstrated our capability for conducting large global trials. In one case, we were chosen in preference to large global CRO’s to conduct a large oncology Phase III trial in four continents.
- We offer sponsors an optimal mix of G8 countries and new economy countries resulting in speedy recruitment at optimal cost and high quality. As per clinicaltrials.gov, a diabetes study managed by us was recruiting patients from the largest number of sites in India, confirming high recruitment by us.
- We are conducting the largest number of stem cell therapy studies in India. Recruitment to a Phase II stem cell therapy trial was completed on time confirming innovative approach in an emerging therapy area.
- Based on studies conducted at our Phase I unit, two global majors got ‘first to file’ clearance from US FDA and Health Canada confirming our understanding of regulator’s expectations in conducting studies.
- In addition to ‘end to end’ services in clinical studies, we provide functional service in SAS, CDM & medical writing, leveraging India. A key FSP client using this service for Europe, extended our service to US in 2010.
- We are seeing a growing requirement of clients to register for marketing in Japan. We entered into a strategic alliance with Tokyo CRO to conduct registration trials in Japan.
- To our direct presence in fast recruiting geographies of India and East Europe, we added Russia and Malaysiacontinuing our expansion.
Ecron Acunova is a CRO built to provide quality on time at competitive cost with personalised service. We welcome you to partner with us in bringing new drugs, therapies and devices to market with innovation and speed.
D. A. Prasanna
Chairman and Founder |
|
|
|
